CURZA
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.
CURZA
Industry:
Biotechnology Health Care Therapeutics
Address:
Salt Lake City, Utah, United States
Country:
United States
Website Url:
http://www.curza.com
Total Employee:
11+
Status:
Active
Contact:
(617) 575-2202
Total Funding:
24.19 M USD
Technology used in webpage:
Microsoft Exchange Online
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Repair Impact Fund
Repair Impact Fund investment in Venture Round - Curza
CARB-X
CARB-X investment in Grant - Curza
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - Curza
American Chemical Society
American Chemical Society investment in Grant - Curza
National Institute of General Medical Science
National Institute of General Medical Science investment in Grant - Curza
U.S. Department of Veteran Affairs
U.S. Department of Veteran Affairs investment in Grant - Curza
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Curza
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Curza
Clarke Capital Partners
Clarke Capital Partners investment in Seed Round - Curza
Official Site Inspections
http://www.curza.com Semrush global rank: 5.89 M Semrush visits lastest month: 1.4 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Curza"
Curza - Crunchbase Company Profile & Funding
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum …See details»
Cūrza Company Profile 2024: Valuation, Funding & Investors
Cūrza General Information Description. Developer of small-molecule therapeutics intended to offer proprietary drugs focused on infectious diseases and oncology. The company's …See details»
Executive Team - Curza
Vice President of Microbiology & New Technologies Dr. Williams is an Associate Professor in the Department of Orthopaedics at the University of Utah and Vice President of New Technologies …See details»
Curza - LinkedIn
Curza | 526 followers on LinkedIn. Small molecule therapeutics R&D company focused on developing new drugs to combat antibiotic resistance | Curza is a small molecule therapeutics development company.See details»
Curza - Funding, Financials, Valuation & Investors - Crunchbase
Curza is a small-molecule therapeutics company provides proprietary drugs focused on infectious diseases and oncology. Search Crunchbase. Start Free Trial . ... How much funding has this …See details»
Curza Company Profile - Office Locations, Competitors, Revenue
Curza Global is a small-molecule therapeutics company that develops drugs for infectious diseases and oncology. It develops ribosomal and antibiofilm antibiotics focused on ESKAPE …See details»
Curza - Org Chart, Teams, Culture & Jobs - The Org
Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead …See details»
Curza - Products, Competitors, Financials, Employees, …
Curza has developed a unique first-in-class series of antimicrobial compounds that kill, disperse and inhibit the growth of bacteria in biofilm communities. Curza’s primary focus is on …See details»
Curza Global, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Curza Global, Inc. of Salt Lake City, UT. Get the latest business insights from Dun & Bradstreet.See details»
Curza Company Profile | Management and Employees List
Find contact information for Curza. Learn about their Business Services market share, competitors, and Curza's email format.See details»
Curza - Crunchbase
Curza is a small-molecule therapeutics company provides proprietary drugs focused on infectious diseases and oncology.See details»
Curza - Company Profile - Tracxn
Curza - US-Based, preclinical stage company developing small molecule therapeutics for Infectious Diseases & Cancer. Raised a total funding of $5.62M over 2 rounds from 1 investor. …See details»
Curza - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and …See details»
Curza - Overview, News & Similar companies | ZoomInfo.com
Jun 25, 2019 Curza Announces $5.25 million Investment from the Novo Holdings REPAIR Impact Fund SALT LAKE CITY, Utah, July 25, 2019 /PRNewswire/ -- Curza, a privately-held …See details»
ABOUT - Curza
Since long before the outbreak of COVID-19, antibiotic resistant bacteria have created a “silent pandemic” that now poses a threat to life as we know it.See details»
Curza - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Curza . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. ... Curza has 1 board …See details»
Press Release 07-25-2019 - curza.com
CŪRZA ANNOUNCES $5.25 MILLION INVESTMENT FROM THE NOVO HOLDINGS REPAIR IMPACT FUNDSALT LAKE CITY, Utah, July 25, 2019 /PRNewswire/ —Cūrza, a privately-held …See details»
NEWS | Curza
Jul 1, 2016 DEPARTMENT OF DEFENSE AWARDS CURZA / UNIVERSITY OF UTAH $2.4 MILLION GRANT Proceeds to Fund Development of Wound VAC Infection Model SALT...See details»
PIPELINE | Curza
We are also developing anti-biofilm antibiotics with various potential applications. Biofilms can cause some of the hardest to treat infections.See details»